To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose Regimen of Ferroquine and Artefenomel in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria
Condition: Plasmodium Falciparum Infection
MeSH terms: Malaria; Malaria, Falciparum
Intervention: Ferroquine SSR97193; Artefenomel; Placebo
Intervention description: Pharmaceutical form:Capsules Route of administration: oral; Pharmaceutical form:Granules for suspension Route of administration: oral; Capsules. Placebo capsules were used to keep the same number of capsules in each weight band while keeping the ferroquine dose blinded. No participant received placebo only.
Intervention MeSH terms: Artefenomel; Ferroquine
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Enrollment: 377.0
Sex: All
Minimum age: 6 Months
Maximum age: 69 Years
Healthy volunteers: No

Summary:

      Primary Objective:

      To determine whether a single dose combination of OZ439 (Artefenomel)/FQ (Ferroquine) was an
      efficacious treatment for uncomplicated Plasmodium falciparum malaria in adults and children.

      Secondary Objectives:

        -  To evaluate the efficacy of OZ439/FQ:

             -  To determine the incidence of recrudescence and re-infection.

             -  To determine the time to relief of fever and parasite clearance.

        -  To evaluate the safety and tolerability of OZ439/FQ in adults and children.

        -  To characterize the pharmacokinetics of OZ439 in plasma, FQ and its active metabolite
           SSR97213 in blood.

        -  To determine the blood/plasma ratio for FQ and SSR97213 in some participants at limited
           time points in selected sites.
    

Eligibility criteria:

        Inclusion criteria:

        Male or female participant aged greater than (>) 6 months old and <70 years old:

          -  Cohort 1 = 14 years < age <70 years and body weight greater than or equal to (>=) 35
             kilogram (kg).

          -  Cohort 2 = 5 years < age less than or equal to (<=) 14 years.

          -  Cohort 3 = 2 years < age <=5 years.

          -  Cohort 4 = 6 months < age <=2 years.

        Body weight >=5 kg and <=90 kg.

        Presence of mono-infection by Plasmodium falciparum with:

          -  Fever, as defined by axillary temperature >=37.5 degrees Celsius (°C) or
             oral/rectal/tympanic temperature >=38°C, or history of fever in the previous 24 hours
             (history of fever must be documented) and,

          -  Microscopically (blood smear) confirmed parasite infection, ranging from 1000 to 100
             000 asexual parasites/microliter of blood.

        Informed consent form signed by the participant or by the legally acceptable representative
        of the minor participant.

        Exclusion criteria:

        Presence of severe malaria.

        Anti-malarial treatment:

          -  With piperaquine-based compound, mefloquine, naphthoquine or
             sulphadoxine/pyrimethamine (SP) within the previous 6 weeks (after their inhibition of
             new infections had fallen below 50%).

          -  With amodiaquine or chloroquine within the previous 4 weeks.

          -  With quinine, halofantrine, lumefantrine-based compounds and any other anti-malarial
             treatment or antibiotics with antimalarial activity (including cotrimoxazole,
             tetracyclines, quinolones and fluoroquinolones, and azithromycin) within the past 14
             days.

          -  With any herbal products or traditional medicines, within the past 7 days.

        Known history or evidence of clinically significant disorders.

        Previous treatment within 5 times the half-life or within the last 14 days, whichever the
        longest which are: P-glycoprotein substrates, Cytochrome P450 (CYP) 2D6 main substrates
        and/or strong CYP2C or CYP3A inhibitors and/or moderate inhibitors but inhibiting both
        CYP2C and CYP3A and/or CYP inducers.

        Mixed plasmodium infection.

        Severe vomiting.

        Severe malnutrition.

        Laboratory parameters with clinically significant abnormalities and/or reaching critical
        values. For Liver Function Test. Aspartate aminotransferase (>2 [upper limit of normal]
        ULN), or alanine aminotransferase (>2 ULN) or total bilirubin >1.5 ULN.

        Presence of Hepatitis A Immunoglobulin M, Hepatitis B surface antigen or Hepatitis C
        antibody.

        Had received an investigational drug within the past 4 weeks.

        Previous participation in any malaria vaccine study or received malaria vaccine in any
        other circumstance.

        Measles and yellow fever vaccine injection within the last 15 days and or planned for the
        28 days after randomization.

        Female participant of child bearing potential not willing to use an effective
        contraceptive(s) method(s) for the duration of the study.

        Positive serum or urine beta-human chorionic gonadotropin pregnancy test at study screening
        for female participants of childbearing potential.

        Breastfeeding women.

        Male participant having a partner of child bearing potential not willing to use an
        effective method of birth control during the study treatment period.

        Splenectomized participants or presence of surgical scar on left hypochondrium. Participant
        unable to drink.

        Known history of hypersensitivity, allergic or anaphylactoid reactions to ferroquine or
        other amino-quinolines or to OZ439 or OZ277 or to any of the excipients.

        Family history of sudden death or of congenital prolongation of the Corrected QT (QTc)
        interval or known congenital prolongation of the QTc interval or any clinical condition
        known to prolong the QTc interval e.g., participants with a history of symptomatic cardiac
        arrhythmias or with clinically relevant bradycardia.

        QTc using Fridericia's formula >450 millisecond at screening or pre-dose.

        Hypokalemia (<3.5 millimoles per liter [mmol/L]), hypocalcemia (<2.0 mmol/L) or
        hypomagnesemia (<0.5 mmol/L) at screening or pre-dose.

        Any treatment known to induce a lengthening of QT interval.

        The above information is not intended to contain all considerations relevant to a
        participant's potential participation in a clinical trial.